News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I (World)
Hovione Announces Start Of Phase l Clinical Trial Of HY02, A Proprietary Minocycline Sterile Ointment To Treat A Subset Of Anterior Ocular Inflammation 5/25/2017
6 (Plus 2!) Most Notable ASCO Abstracts So Far 5/24/2017
BioLineRx Announces Regulatory Submission For Phase Ib Trial Of BL-8040 In Combination With Atezolizumab In AML 5/22/2017
Regeneus (RGS.AX) Positive Clinical Trial Results For Progenza 5/22/2017
ADC Therapeutics Doses First Patient In A Phase I Clinical Trial Of ADCT-502 In Patients With Advanced Solid Tumors With HER2 Expression 5/19/2017
ObsEva (OBSV) Announces The Completion Of A Phase I Drug-Drug Interaction Study With OBE022 5/18/2017
Patient Treatment Commences In Cynata’s World First Clinical Trial 5/17/2017
Galapagos (GLPG.BR) Release: Seven Abstracts On Filgotinib Accepted By EULAR 2017 5/16/2017
Probiodrug AG Announces Acceptance Of PQ912 Pharmacology Paper By Peer Reviewed Journal 5/16/2017
Zealand Pharma  (ZEAL.CO) Discloses Amylin As The Biological Target Under Their 2014 Agreement With Boehringer Ingelheim 5/11/2017
4 Biotechs That Could Release Stock-Shattering Data Soon 5/11/2017
Sierra Oncology Receives Clearance To Enhance Ongoing Clinical Trials For SRA737 5/10/2017
Targovax Recruits First Patient Into First ONCOS-102 /Checkpoint Inhibitor Melanoma Study 5/10/2017
Oncoquest Announces Enrollment Of First Patient In Phase I/II Clinical Study Using Combination Of Oregovomab With Checkpoint Inhibitor Nivolumab In Recurrent Ovarian Cancer 5/9/2017
Protalix (PLX) Announces FDA Investigational New Drug Clearance To Commence Once-Monthly Dosing Study Of Pegunigalsidase Alfa (PRX-102) For The Treatment Of Fabry Disease 5/9/2017
Botanix Commences First Clinical Study For BTX 1503 5/8/2017
4 Biotechs That Could Explode Or Crash In May 5/5/2017
SGS Life Science Services (SGSN) Clinical Research Announces Results Of First-In-Human Studies Using Novel Virus As Experimental Challenge Agent 5/5/2017
Hookipa Biotech Presents Positive Data From Phase I First-In-Human Trial Of Vaccine Against Cytomegalovirus 5/4/2017
YiSheng BioPharma Starts China Phase I Trial Of Immuno-Oncology Candidate 5/4/2017
YiSheng BioPharma Starts Enrollment In Phase I Immuno-Oncology Clinical Trial Of YS-ON-001 In Patients With Advanced Solid Tumors 5/1/2017
ProQR Therapeutics B.V. (PRQR) Announces Clearance Of IND Application To Start Clinical Trial For QR-110 In Leber’s Congenital Amaurosis Type 10 Patients 4/27/2017
PIQUR Therapeutics AG Receives EMA Orphan Drug Designation For PQR309 In Diffuse Large B-Cell Lymphoma 4/27/2017
Amazentis Announces Successful Phase IA/IB Study Results In Healthy Elderly Subjects With The Food Metabolite Urolithin A 4/27/2017
First Patient Treated In Turnstone Biologics's Lung Cancer Trial Combining Novel Viral Cancer Therapy With Approved Checkpoint Inhibitor 4/26/2017
ReViral Announces Good Safety And Pharmacokinetics From Phase I Programme For RSV Antiviral RV521 In Healthy Volunteers 4/24/2017
Top 15 R&D Spenders In The World For 2017 4/24/2017
Tiziana Life Sciences Plc Announces Publication Of Peer-Reviewed Paper From Positive Clinical Trial Of Milciclib In Patients With Refractory Solid Tumours 4/21/2017
RedHill Biopharma (RDHL) Announces Peer-Reviewed Publication Of The Positive YELIVA Phase I Study Results In Advanced Solid Tumors 4/20/2017
BTG plc (BTG.L) Release: First European Patients Treated With Dc Bead Lumi Radiopaque Drug-Eluting Beads 4/20/2017
Prima Biomed (PRR.AX) Receives Approval For Third Cohort Of Phase I Melanoma Trial 4/20/2017
Prima Biomed (PRR.AX) Receives Approval For Third Cohort Of Phase I Melanoma Trial 4/19/2017
Eyevensys Receives Approval From The French Product Security Regulatory Agency ANSM To Advance Its Eyecet Platform Into Clinical Development 4/11/2017
Zika Virus: Themis Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine 4/11/2017
3 Drug Giants That Boasts the Best Pipelines 4/11/2017
Galapagos (GLPG.BR) Doses First Psoriatic Arthritis Patient With Filgotinib 4/6/2017
Asceneuron Receives Regulatory Approval For Phase I Healthy Volunteer Study Of Oral Tau Inhibitor 4/6/2017
Cardiome Pharma Corp. (COM.TO)'s Partner SteadyMed (STDY) Announces Successful Completion Of Trevyent Clinical Validation Study 4/6/2017
China FDA Accepts JHL Biotech's First Clinical Trial Application 4/5/2017
ASIT Biotech Announces That It Has Achieved The Primary Endpoint Of The Phase I/IIa Clinical Trial With Its hdm-ASIT+ Product Candidate For House Dust Mite Rhinitis 4/5/2017
ABIVAX Initiates Clinical Trial (ABX464-005) To Evaluate The Effect Of ABX464 On HIV-Reservoirs In HIV Patients 4/5/2017
Common Antibiotic May Help To Prevent Or Treat PTSD, University of Zurich Study Reveals 4/4/2017
RedHill Biopharma (RDHL) Receives FDA Orphan Drug Designation For YELIVA For The Treatment Of Cholangiocarcinoma 4/4/2017
Nanobiotix Expands Its Clinical Development In Head And Neck Cancer And I/O 4/4/2017
Biovica Release: DiviTum Results In Blockbuster Drug Study Presented At AACR 4/3/2017
ESSA Pharma Provides Clinical Study Update And Announces Presentations At The AACR Annual Meeting 4/3/2017
Clinical Results Presented From Prothena (PRTA)’s Phase Ib Study Of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration And Significant Reduction Of Free Serum Alpha-Synuclein In Patients With Parkinson’s Disease 4/3/2017
Oncodesign SA Presents Its Latest Scientific Developments At The AACR Annual Global Meeting On Oncology 4/3/2017
Phase I Clinical Trial Completes Using Cell Line Expertise At Cobra Biologics Ltd. 4/3/2017
DBV Tech, BioNet-Asia And Geneva University Hospitals Announce Phase I Trial Results Of Viaskin rPT In Pertussis Booster Vaccination 3/31/2017
Avillion Signs Clinical Co-Development Agreement With Merck & Co. (MRK) To Advance Anti IL-17 A/F Nanobody In Psoriasis 3/30/2017
JHL Biotech Doses First Patient In JHL1101 Phase I European Trial 3/29/2017
Compugen Ltd. (CGEN) Announces Lead Therapeutic Candidate COM902 For CGEN-15137/TIGIT Immuno-Oncology Program 3/28/2017
MediGene AG (MDGEF.PK): Announces Target And Outlines Design For Its First Clinical Trial In TCR Cancer Immunotherapy (MDG1011) 3/23/2017
Intec Pharma Initiates Phase I Trial Of Accordion Pill For Cannabinoid Therapies 3/22/2017
Minoryx Therapeutics Successfully Completes Phase 1 Clinical Trial For Lead Candidate MIN-102 3/21/2017
WntResearch Announces Positive Results From Clinical Study With Drug Candidate Foxy-5 3/21/2017
Replicel Life Sciences's Phase I Clinical Trial For Hair Loss Succeeds In Meeting Primary Endpoints 3/14/2017
Lung Therapeutics Doses First Patient In Phase I Clinical Trial Of LTI-01 In Australia And New Zealand 3/14/2017
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders 3/8/2017
Renown Pharma Announces Successful Results Of Apomorphine Sub-Lingual Spray Pharmacokinetic Study To Treat "OFF" Episodes In Parkinson's Patients 3/7/2017
Herantis Pharma's Clinical Study With Lymfactin Advances To High Dose Level 3/7/2017
Trillium Therapeutics Provides Additional Details On ASCO-SITC Conference Presentation On TTI-621 2/24/2017
Acticor Biotech Has Selected Its Contract Research Organization To Manage Clinical Study Phase I 2/23/2017
Boston Scientific (BSX) Sinks After Recalling All Lotus Heart Valves 2/23/2017
hVIVO Services Limited Notes The Initiation Of A Phase I Clinical Trial With AGS-V, A Mosquito-Borne Disease Vaccine Candidate 2/21/2017
Could Marijuana Be the Next Miracle Drug For Treating Cancer? 2/20/2017
Hutchison China MediTech (Chi-Med) Initiates First-In-Human Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In Australia 2/14/2017
Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval 2/14/2017
Hutchison China MediTech (Chi-Med): Initiates Phase I Of Novel FGFR Inhibitor HMPL-453 2/14/2017
Hutchison China MediTech (Chi-Med) Launches Phase I Trial Of Novel FGFR Inhibitor In Australia 2/14/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters 2/14/2017
Vyome Announces Top-Line Results From Phase 1 Study Of VB-1953 For Patients With Facial Acne Vulgaris 2/7/2017
No Looking Back: Cellectis (CLLS) Preps for Cutting-Edge 'Off-the-Shelf' CAR-T Trial 2/7/2017
GlaxoSmithKline (GSK)'s Incoming CEO Preps for Deals, R&D Decisions on New Drugs 2/7/2017
Auris Med (EARS) Expands Clinical Development Pipeline With Intranasal Betahistine For The Treatment Of Meniere's Disease And Vestibular Vertigo 2/6/2017
Lysogene Receives Orphan Drug Designation From FDA For LYS-GM101 For Treatment Of GM1 Gangliosidosis 2/3/2017
Phase I Clinical Data Of ABX464, ABIVAX's First-In-Class Anti-HIV Drug, Published In Two Articles In Peer-Reviewed Journals 2/3/2017
Auris Med (EARS) Expands Beyond Cochlear Therapies To Include Vestibular Therapy: Intranasal Betahistine, AM-125 2/3/2017
Scientists Highlight the Hopes and Fears of Cellectis (ALCLS)' CAR-T 1/26/2017
Novartis AG (NVS) Shows Off 13 Potential Blockbusters in Pipeline 1/25/2017
Swedish Orphan Biovitrum Release: First Patients Enrolled In 24 Month Real-World Study Evaluating Effectiveness Of Elocta 1/19/2017
Lysogene Release: Biotech Receives Rare Pediatric Disease Designation From FDA For LYS-GM101 For Treatment Of GM1 Gangliosidosis 1/18/2017
WuXi AppTec Release: Novel Anti-IL-6 Antibody For Rheumatoid Arthritis From WuXi-MedImmune (AZN) Joint Venture Receives Clinical Trial Permit (CTP) From CFDA 1/18/2017
Daiichi Sankyo Release: Company Initiates Phase 1/2 Study Of Novel Antibody Drug Conjugate U3-1402 In Patients With HER3-Positive Metastatic Or Unresectable Breast Cancer 1/18/2017
Hutchison China MediTech (Chi-Med) Release: Company Presents Phase I/II Clinical Data For Selective VEGFR Inhibitor Fruquintinib At The 2017 Gastrointestinal Cancers Symposium 1/16/2017
ObsEva Release: Company Announces Completion Of Phase I First-In-Women Study Of OBE022 For The Treatment Of Preterm Labor 1/13/2017
Celyad Release: Biotech Announces Registration Of The First Pancreatic Cancer Patient In Its CAR-T NKR-2THINK Trial In Belgium 1/12/2017
Affimed (AFMD) Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform 1/11/2017
Mologen (MOLGF.PK) Release: Grant To Collaboration Partner For Combination Study In HIV With Lead Product Lefitolimod 1/10/2017
Hutchison China MediTech (Chi-Med) Release: Company Initiates HMPL-523 Clinical Trials In Hematological Cancer In China 1/10/2017
Sierra Oncology Successfully Transfers Sponsorship Of SRA737 Clinical Trials 1/9/2017
RedHill Biopharma (RDHL) Announces YELIVA (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference 1/6/2017
Enterome Starts Phase I Clinical Trial With Its Lead Candidate EB8018 To Treat Crohn's Disease 1/5/2017
Minervax Announces Positive Results From Phase I Trial In 240 Healthy Adult Women With Its Innovative Group B Streptococcal (GBS) Vaccine To Prevent Life-Threatening Infections In Newborns 1/5/2017
BeiGene (BGNE) Doses First Patient In China Phase I PARP Trial 12/27/2016
Inovio Pharma (INO)’s Zika Vaccine Generates Robust Immune Responses In First Human Study 12/21/2016
Astellas (ALPMY) Announces FDA Fast Track Designation For ASP0892, DNA Vaccine For Mitigation Of Severe Hypersensitivity Reactions Due To Peanut Allergy 12/20/2016
DRGT's Novel Celecoxib Composition - Opportunity For Low Dose, Immediate Onset Of Pain Relief With The Only NSAID COX-2 Inhibitor On The Market 12/19/2016
Enyo Pharma Announces Successful Initiation Of The Phase 1 Clinical Programme With EYP001, Its Lead Candidate For The Treatment Of Chronic Hepatitis B Virus Infection 12/16/2016
Minoryx Therapeutics Receives European Orphan Drug Designation For Its Lead Candidate MIN-102 12/14/2016
Vyome Presents On Development Of Dual Action Rational Therapeutics (Darts) To Treat Infections Caused By Antibiotic-Resistant Skin Opportunist Pathogens At Re-Entering Antibacterial Discovery And Development Summit 2016 12/8/2016
BerGenBio AS Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML At American Society of Hematology 2016 12/6/2016
Gamida Cell Presents Positive Data From Phase 1/2 Study Of NiCord as A Curative Treatment For Sickle Cell Disease At American Society of Hematology 2016 12/6/2016
Akari Therapeutics Announces Corporate Update With New Positive Clinical Data And A New Pipeline Of Tick Derived And Engineered Proteins 12/5/2016
AstraZeneca PLC (AZN) Release: Early Data Demonstrate Clinical Activity Of Acalabrutinib In Difficult-To-Treat Chronic Lymphocytic Leukemia 12/5/2016
NeuroDerm (NDRM) Announces Top-Line Results Of Pilot PK Trial Comparing ND0701 With Commercial Apomorphine 12/2/2016
BerGenBio AS Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML At American Society of Hematology 2016 12/2/2016
ERYtech Pharma Presents New Data On GRASPA’s Mechanism Of Action At American Society of Hematology Annual Meeting 12/1/2016
Cellular Biomedicine Group (CBMG), A China-US Biopharma, Starts China Trial Of CAR-T Immunotherapy 12/1/2016
PharmaMar Begins A Phase I Study Of PM1183 In Japan For The Treatment Of Solid Tumors 11/28/2016
Nature Cell Receives U.S. FDA Approval For Phase I And II Alzheimer's Clinical Trial 11/28/2016
YiSheng BioPharma Announces Completion Of Phase I Clinical Study Of A Novel Hepatitis B Vaccine With PIKA Adjuvant 11/21/2016
DBV Tech, BioNet-Asia And Geneva University Hospitals Complete Dosing In First Cohort Of Phase I Study Of Viaskin Rpt For Booster Vaccination Against Pertussis 11/17/2016
China Takes Lead in CRISPR Race, Will Test on a Human for the First Time 11/16/2016
Hutchison China MediTech (Chi-Med) Presents Phase I Clinical Data For Selective Syk Inhibitor HMPL-523 At The 2016 American College of Rheumatology/ARHP Annual Meeting 11/14/2016
MiNA Presents Data Demonstrating Survival Benefit Of MTL-CEBPA In Animal Model Of Liver Failure At AASLD Liver Meeting 11/14/2016
Innate Pharma (IPH.PA ) Stock Falls Then Bounces Back as Prelim Opdivo Combo Data Fails to Impress 11/9/2016
Eloxx Pharma Announces Orphan Drug Designation In The U.S. And Europe For ELX-02 In Mucopolysacchardisis Type 1 (MPS 1) 11/8/2016
Elanix Technologies Strategic Partner, Transwell Biotechnology, Receives U.S. FDA Clearance For Phase I/II Clinical Trial Using Fibroblast Progenitors TWB-103 11/8/2016
Celyad's CAR-T Candidate Delivers in Early Stage Study 11/7/2016
Sanofi (SNY) and Novartis AG (NVS) are the Worst Culprits in Reporting Clinical Trial Data, Shire (SHPG) the Best 11/4/2016
Karolinska Development AB Umecrine Cognition Announces Positive Phase 1 Data With GR3027 In Hepatic Encephalopathy 11/3/2016
Towards The Company's First Clinical Trial; Kadimastem Signs Letter Of Intent With Hadassah Medical Center For Performance Of The Clinical Trial In ALS 11/3/2016
Momenta (MNTA) And Mylan (MYL) Initiate Phase I Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA (Abatacept) 11/2/2016
OncoVent Release: Initiates Clinical Development Program For Anti-MUC1 MAb AR20.5 For Treatment Of Pancreatic Cancer 11/2/2016
Vyome Administers First In-Human Dose Of VB 1953 In U.S. Phase I Clinical Study In Patients With Facial Acne Vulgaris 10/31/2016
ReViral Initiates Phase 1 Clinical Trial Of Potent Oral Inhibitor Against Respiratory Syncytial Virus 10/31/2016
Adocia Announces Positive Topline Results From A Phase 1b Clinical Trial Measuring The Post-Meal Effect Of Rapid-Acting Human Insulin, Hinsbet U100 10/31/2016
Philogen S.p.A. Receives Orphan Drug Designation For The Treatment Of Soft Tissue Sarcoma 10/28/2016
Innate Pharma (IPH.PA ): Encouraging Initial Results For IPH4102 Presented At The Third World Congress Of Cutaneous Lymphomas 10/27/2016
ProQR Therapeutics B.V. (PRQR) Announces That QR-010 Meets The Primary Endpoint In A Proof Of Concept Study Of Homozygous F508del Cystic Fibrosis Patients 10/27/2016
F2G Announces Publication Of Initial F901318 Data In Scientific Journal PNAS 10/26/2016
National Center for Child Health And Development Initiates Phase 1/2 Trial Of Green Cross' Idursulfase-Beta ICV For The Treatment Of Hunter Syndrome With Neurocognitive Decline 10/26/2016
Theravance Biopharma (TBPH) Announces Positive Results Including Biomarker Data From Phase 1 Multiple-Ascending Dose Study Of TD-0714, An Inhibitor Of Neprilysin (NEP) 10/25/2016
Alphamab Starts Clinical Trial On Its First Novel Biologics KN015, A Long-Acting FSH, For In Vitro Fertilization (IVF) 10/24/2016
MorphoSys AG Receives Clinical Milestone For Start Of Phase 1 Trial With Novel Cancer Antibody 10/21/2016
PharmaEngine, Inc. Announces Initiation Of Phase 1b/2 Trial Of PEP503 (NBTXR3) In Head And Neck Cancer 10/19/2016
Adaptimmune (ADAP) Announces Initiation Of Triple Tumor Study To Evaluate Its SPEAR T-Cell Therapy Targeting MAGE-A10 10/18/2016
Bayer (BAY) is Pumped Up About Its Potential Cancer Blockbuster But Investors are Skeptical 10/18/2016
First Patient Randomized In Multiple Dose Cohort Of Phase 1/1b Trial With TRANSGENE (ENX:TNG)'s TG1050 In Chronic Hepatitis B Patients 10/17/2016
Celgene (CELG) Release: Oral GED-0301 Phase 1b Results Show Clinical Remission And Endoscopic Response At Week 12 In Patients With Active Crohn's Disease 10/17/2016
Chromocell And Astellas (ALPMY) Announce FDA Fast Track Designation And First Subject Dosing With Lead Candidate CC8464/ASP1807 For The Management Of Neuropathic Pain Associated With iSFN 10/13/2016
Adaptimmune (ADAP) Makes Move to Save Ovarian Cancer Study By Readjusting Its Trial Protocol 10/12/2016
TRANSGENE (ENX:TNG) Announces Collaboration With Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) To Evaluate The Combination Of TG4001 With Avelumab In HPV-Positive Head & Neck Cancer In A Phase I/II Study 10/11/2016
OncoMed (OMED) Presents Interim Phase Ib Data For Ipafricept And Vantictumab In Pancreatic Cancer At The ESMO 2016 Congress 10/10/2016
Novartis AG (NVS) Challenges Pfizer (PFE) Full on With New Breast Cancer Data 10/10/2016
Karus Therapeutics Announces First Lymphoma Patients Dosed With KA2237 In Clinical Study At MD Anderson Cancer Center 10/5/2016
BTG plc (BTG.L) Release: First Patient In Malaysia Receives TheraSphere Radioembolisation Therapy 10/4/2016
Alkermes (ALKS) Announces Initiation Of Clinical Study Evaluating Metabolic Profile Of ALKS 3831 For Treatment Of Schizophrenia 10/3/2016
First Patient Dosed In CANBridge Life Sciences’s CAN-008 Phase I/II Trial In Newly-Diagnosed Glioblastoma Multiforme In Taiwan 9/26/2016
China Biologic Products Receives CFDA Clinical Trial Approval For Human Coagulation Factor IX 9/19/2016
UK Regulatory Authority Approves Cynata GvHD Clinical Trial 9/19/2016
Parkinson’s Disease: Prexton Therapeutics Completes Phase 1 Clinical Trial 9/19/2016
Xenikos: Last Patient Treated In Phase 1/2 Trial With T-Guard In Acute Graft-Versus-Host Disease 9/15/2016
Inotrem Successfully Completes Its First Phase I Clinical Trial With Motrem, A TREM-1 Pathway Modulator For The Treatment Of Septic Shock 9/13/2016
RedHill Biopharma (RDHL) Announces Phase Ib/II Study With YELIVA Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center 9/8/2016
BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications 9/7/2016
Boost Vaccination Data Encourage Continued Development of AFFiRiS AG Therapeutic Parkinson's Disease Vaccine Against Alpha-Synuclein 9/7/2016
Sensorion Announces Positive Results From SENS-218 Phase I Clinical Trial Undertaken In The UK 9/7/2016
GenSight Biologics Receives Orphan Drug Designation And Advanced Therapy Medicinal Product Classification In Europe For GS030 In Retinitis Pigmentosa 9/1/2016
Neurimmune Therapeutics Release: Early Results Show Aducanumab Removes Amyloid Plaques In Patients With Alzheimer’s Disease 8/31/2016
BirchBioMed Announces Completion Of Clinical Trial For Ground-Breaking Anti-Scarring Drug 8/26/2016
Zymeworks’ ZW25 And ZW33 Granted Orphan Drug Designation for Ovarian Cancer By U.S. FDA 8/18/2016
Protalix Biotherapeutics, Inc. (PLX) Announces Additional Positive Data From Its Phase I/II Clinical Trial For PRX-102 For The Treatment Of Fabry Disease 8/10/2016
Novartis AG (NVS)'s New Asthma Drug Hailed a Game-Changer After Success in Small Trial 8/9/2016
Can-Fite BioPharma (CFBI)'s Phase II/III Psoriasis Study Results Published In Journal Of Drugs In Dermatology 8/8/2016
Evotec AG (EVTG.F) Achieves Clinical Development Milestone As Part Of Its Multi-Target Alliance With Bayer (BAY) In Endometriosis 8/4/2016
The Results Of Phase I Clinical Trial Of The Araclon Biotech Alzheimer's Vaccine Support Its Continuation 8/1/2016
AstraZeneca PLC (AZN) Kills Six Pipeline Programs 7/28/2016
Stemedica Cell Technologies, Inc. Begins First Clinical Trials In The U.S. Using Adult Allogeneic Stem Cells To Treat Alzheimer's Disease 7/27/2016
Gamida Cell Announces First Patient With Sickle Cell Disease Transplanted In Phase 1/2 Study Of Cordin As The Sole Graft Source 7/27/2016
Symcel Secures Phase I Horizon 2020 Grant As The Company Plans For Full Scale Commercialisation Of calScreener – The World’s First Multi Channel Calorimetry System For Antimicrobial Susceptibility Testing 7/27/2016
Adaptimmune (ADAP) Receives Orphan Drug Designation In The European Union For Its NY-ESO SPEAR T-Cell Therapy For Treatment Of Soft Tissue Sarcoma 7/26/2016
GlaxoSmithKline (GSK) Becomes First Drug Firm to Use Apple (AAPL)’s ResearchKit for Clinical Research 7/18/2016
Akari Therapeutics Receives Positive Opinion For Orphan Drug Designation For Coversin In The European Union For Treatment Of Paroxysmal Nocturnal Hemoglobinuria 7/12/2016
VAXIMM Initiates Phase 1 Translational Study In Glioblastoma With Oral T-Cell Immunotherapy, VXM01 7/12/2016
uniQure (QURE) Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress 7/11/2016
Nanobiotix Reports Successful Results From Phase I/II Trial Of NBTXR3 In Head & Neck Cancer 7/7/2016
China's BeiGene (BGNE) Starts Combination Trial For Two Novel Cancer Drugs 7/7/2016
Scancell (SCNLF) Delays Melanoma Trial 9 to 12 Months to Whip Up New Batch of Cancer Vaccine 7/7/2016
Minoryx Therapeutics Initiates Phase 1 Clinical Trial Of MIN-102 7/6/2016
Initiation Of Phase 1 Clinical Study With Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca PLC (AZN) 7/6/2016
Heptares Anounces Initiation Of Phase 1 Clinical Study With Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca PLC (AZN) 7/6/2016
Lysogene Begins Multi-National Observational Study As It Prepares To Initiate Pivotal Clinical Trial For The Treatment Of Sanfilippo Type A 7/6/2016
First-In-Human Study Of Immbio's Novel Pneumococcal Vaccine Pnubiovax Shows Vaccine To Be Safe And Immunogenic 6/30/2016
PsiOxus Gets Upfront $10 Million, Ties Immuno-Oncology Clinical Pact With Bristol-Myers Squibb (BMY) 6/30/2016
Symphogen Advances Sym015 Into Clinical Development Using Selexis SA SGEs (Selexis Genetic Elements) 6/29/2016
Neuromax Announces Start Phase 1 Clinical Trial Of AQU-005 For The Treatment Of Neuropathic Pain 6/28/2016
Roche (RHHBY) CEO 'Sleeping Much Better' Following Positive News About Three New Drugs 6/23/2016
Scancell (SCNLF) Suspends Dosing in Melanoma Trial Due to Quality Issues 6/17/2016
uniQure (QURE) Presents Clinical Data From Ongoing Phase I/II Study In Hemophilia B Demonstrating 6 Months Of Sustained Increases In Factor IX Activity 6/13/2016
BioTime (BTX)’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval To Start Second Patient Cohort In Clinical Trial For Dry-AMD 6/13/2016
Nordic Nanovector: Pre-Dosing NHL Patients With HH1 Anti-CD37 Antibody Before Betalutin® Increases Its Pharmacokinetic Exposure And Reduces Its Haematological Toxicity 6/10/2016
Galderma Laboratories Trifarotene Development Program Meets Key Milestone For Lamellar Ichthyosis Orphan Disease 6/9/2016
Paradigm Provides Clinical Trial Update 6/9/2016
GenSight Biologics Announces Additional Promising Results Of Its Phase I/II Study With GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON) 6/8/2016
ASCO2016: BerGenBio AS Reports First-In-Patient Phase 1 Data For BGB324 In Patients With Myeloid Malignancies At The 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting 6/7/2016
Living Cell Tech's NTCELL Demonstrates Continued Reversal Of Parkinson's Disease 6/7/2016
ASCO2016: Gamida Cell Presents Data From Phase 1/2 Study Of Nicord For High Risk Hematological Malignancies At ASCO 2016 6/6/2016



//-->